2 Hot Analyst Reads For Monday, August 13th

Bret Jensen

Better a good journalist than a poor assassin.” ― Jean-Paul Sartre

Sign Up Free Today: To comment on this article or to get and read these full articles free every day before the market open to your ‘in box’ as published, just hit the + Follow button in the upper right-hand corner of this site.

The market looks like it will start a new trading week on an up note based on pre-market futures. Last week, the market was mixed as the S&P 500 and the Dow posted small losses while the NASDAQ and Russell 2000 rose slightly. Turkey emerged as the latest worry for investors late in the week.

To start the week, here are two small cap names garnering analyst commentary just before the market opens this Monday.

Stemline Therapeutics (STML) is reissued as a Buy with a $30 price target at Roth Capital this morning, primarily on upcoming FDA events. Here is the color from Roth's analyst

"We expect acceptance of the Elzonris BLA by end-August, and approval of a label in front-line BPDCN by early 1Q19. In parallel to the commercial launch in BPDCN next year, we guide investor attention to the opportunity and progress in lateral indications, such as CMML, which in our view may easily and quickly compound the value of Elzonris. We reiterate our Buy rating and $30 price target."

The FDA accepted the company's marketing application for ELZONRIS soon after this call was made this morning.

ADMA Biologics (ADMA) continues to pick positive analyst mentions after a couple of positive events. Today it is Oppenheimer reissuing a Buy rating with $13 price target and the following commentary

ADMA’s 2Q18 net loss per share of $0.35 matched our estimate. Following progress with the Boca Raton manufacturing facility (2H17 remediation, April 2018 inspection and Form 483 responses) that ADMA acquired from former CMO Biotest, we believe its current status will support re-registration of Bivigam under a new fractionation process (10/25/18 PDUFA, ~$60M historical sales) and approval of RI-002 (to re- submit BLA in 2H18, we forecast $200M+ in peak sales). We view ADMA as an innovative, up-and-coming player in the growing ~$5.5B worldwide immunoglobulin market. Mid-2017 gain of manufacturing ownership/control has put company on a road to cure CMC deficiencies material to its business plan, and we expect shares to continue their upward move as ADMA executes on its 2018-19 goals.”

And those are two small cap concerns seeing recent analyst activity before the market opens for the first trading session of the week. Happy Hunting. .

FreeReport Available: My colleagues at Investors Alley have just published a free report entitled '10 Simple Rules To Trade Options Like A Pro' for those that want to learn more about profitably adding options strategies to their investing 'toolbox' including Buy-Writes on many of the small caps we cover in these pieces, it is now available free via download HERE.


Hot Analyst Reads